BiotechTube

Abituzumab 1500 mg + Abituzumab 500 mg + Placebo

Phase 2Terminated
1 views this week 0 watching💤 Quiet
Interest: 27/100
27
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Systemic Sclerosis-associated Interstitial Lung Disease

Conditions

Systemic Sclerosis-associated Interstitial Lung Disease

Trial Timeline

May 31, 2016 → May 30, 2018

NCT ID
NCT02745145

About Abituzumab 1500 mg + Abituzumab 500 mg + Placebo

Abituzumab 1500 mg + Abituzumab 500 mg + Placebo is a phase 2 stage product being developed by Merck for Systemic Sclerosis-associated Interstitial Lung Disease. The current trial status is terminated. This product is registered under clinical trial identifier NCT02745145. Target conditions include Systemic Sclerosis-associated Interstitial Lung Disease.

What happened to similar drugs?

10 of 20 similar drugs in Systemic Sclerosis-associated Interstitial Lung Disease were approved

Approved (10) Terminated (4) Active (7)
✅Baricitinib + CyclophosphamideEli LillyApproved
✅Rosuvastatin + SimvastatinAstraZenecaApproved
✅AnifrolumabAstraZenecaApproved
✅EfalizumabMerckApproved
✅AmbrisentanGilead SciencesApproved
✅BMS-986165Bristol Myers SquibbApproved
✅versus hydroxychloroquineSanofiApproved

Hype Score Breakdown

Clinical
12
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02745145Phase 2Terminated

Competing Products

20 competing products in Systemic Sclerosis-associated Interstitial Lung Disease

See all competitors
ProductCompanyStageHype Score
Tabalumab Auto-Injector + Tabalumab Prefilled SyringeEli LillyPhase 3
32
Baricitinib + PlaceboEli LillyPhase 2
35
MRA(Tocilizumab) + placeboChugai PharmaceuticalPhase 3
40
MRA(Tocilizumab)Chugai PharmaceuticalPhase 3
40
MRA(Tocilizumab)Chugai PharmaceuticalPhase 3
40
DS-7011a + PlaceboDaiichi SankyoPhase 1
29
DS-7011a + PlaceboDaiichi SankyoPhase 1/2
32
Bocidelpar + PlaceboAstellas PharmaPhase 1
21
Parenteral micafungin application + Other parenteral antifungal drugsAstellas PharmaPre-clinical
26
MicafunginAstellas PharmaPhase 2
35
E6742EisaiPhase 1/2
32
KHK4827Kyowa KirinPhase 1
29
KHK4827 + PlaceboKyowa KirinPhase 3
40
Baricitinib + PlaceboEli LillyPhase 3
40
Baricitinib + CyclophosphamideEli LillyApproved
47
Baricitinib + PlaceboEli LillyPhase 3
32
LY2127399 + Placebo every 2 weeks + Placebo every 4 weeks + Standard of CareEli LillyPhase 3
40
LY3361237 + PlaceboEli LillyPhase 2
27
LY2127399 + PlaceboEli LillyPhase 3
32
LY3361237 + PlaceboEli LillyPhase 1
29